Yueyun Chen

Chengdu, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial.

Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial.

Journal: Future oncology (London, England)
Published: July 14, 2026

Correction: Lin et al. Prospects and Challenges of Lung Cancer Vaccines. Vaccines 2025, 13, 836.

Correction: Lin et al. Prospects and Challenges of Lung Cancer Vaccines. Vaccines 2025, 13, 836.

Journal: Vaccines
Published: June 04, 2026

Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma.

Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma.

Journal: Cell host & microbe
Published: October 14, 2025

Optimal combination of immune cells for predicting outcomes in ESCC patients following neoadjuvant immunochemotherapy: Results from a prospective phase II trial.

Optimal combination of immune cells for predicting outcomes in ESCC patients following neoadjuvant immunochemotherapy: Results from a prospective phase II trial.

Journal: Genes & diseases
Published: September 18, 2025

Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.

Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.

Journal: Frontiers in immunology
Published: July 03, 2025

Prospects and Challenges of Lung Cancer Vaccines.

Prospects and Challenges of Lung Cancer Vaccines.

Journal: Vaccines
Published: June 20, 2025

A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer.

A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer.

Journal: Oncology research
Published: April 29, 2024

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion.

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion.

Journal: Current oncology (Toronto, Ont.)
Published: September 23, 2023

Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer.

Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer.

Journal: Scientific reports
Published: September 24, 2022

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.

Journal: Frontiers in oncology
Published: July 29, 2022

Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer.

Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer.

Journal: Cancer management and research
Published: November 02, 2021

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: September 17, 2021
Showing 1-12 of 16

Last Updated: 09/26/2026